Starling Oncology, Inc. (STLN) stock price, financials & research

Regular session · ET · Market data may be delayed.

Company profile

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

Industry: Medical - Care Facilities
Sector: Healthcare
Headquarters: US
CEO: Daniel Virnich
Listed since: Aug 4, 2026
Employees: 641

Market position

Day range

Current $6.465

$6.365$6.75

52-week range

Current $6.465

$2.32$7.05

Open: $6.62
Previous close: $6.54
Volume: 1.53M; 0.82× average
Average volume: 1.86M; Average daily volume
Market cap: 646.39M USD
Beta: 0.41; Market reference 1
50-day average: $5.5576; +16.33% above average
200-day average: $3.9772; +62.55% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -21.55×
P/B (TTM): -26.74×
P/S (TTM): 1.1×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 15.69%
Operating margin: -4.44%
Net margin: -6.18%

Financial health

Debt / equity: -4.19×

Financial statements

Metric (USD)	FY2025
Revenue	502.73M USD
Cost of goods sold	426.29M USD
Gross profit	76.44M USD
Selling, general, and administrative	105.57M USD
Operating expenses	112.52M USD
Interest expense	11.28M USD
Depreciation and amortization	6.94M USD
Operating income	−36.08M USD
Net income	−60.61M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 25%; 1 beat, 3 misses, 0 met estimates
Average EPS surprise: -15.44%; 4 comparable reports
Latest EPS result: -0.08; Estimate -0.06 · Miss by 25.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%

Buy3100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

3 institutions

B. Riley SecuritiesmaintainBuyMar 13, 2026

STLN news

globenewswire.comAug 17, 2026

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the…

Read source

seekingalpha.comAug 7, 2026

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Read source

zacks.comAug 6, 2026

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.

Read source

globenewswire.comAug 6, 2026

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported…

Read source